Business Context and Reporting Period
Company: MetaVia Inc. (formerly NeuroBo Pharmaceuticals, Inc.)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: MetaVia is a clinical-stage biotechnology company focused on developing novel pharmaceuticals for cardiometabolic diseases. The company's primary pipeline consists of two assets: DA-1241 (a GPR119 agonist for MASH and Type 2 Diabetes) and DA-1726 (a GLP-1/GCGR dual agonist for obesity). The company also holds four legacy programs (ANA001, NB-01, NB-02, Gemcabene) which are not being actively advanced and are considered for out-licensing.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(27,592) | $(12,470) |
| Loss Per Share (Basic & Diluted) | $(3.56) | $(2.46) |
| Total Operating Expenses | $28,809 | $15,886 |
| Research & Development (R&D) | $21,553 | $9,158 |
| General & Administrative (G&A) | $7,256 | $6,728 |
| Cash and Cash Equivalents (Dec 31, 2024) | $16,017 | $22,435 |
| Accumulated Deficit (Dec 31, 2024) | $(135,857) | $(108,265) |
| Net Cash Used in Operating Activities | $(24,710) | $(10,799) |
| Net Cash Provided by Financing Activities | $18,300 | $(80) |
Note: The filing text does not provide specific margin data as the company has generated no revenue.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased by $12.9 million (81.3%) to $28.8 million in 2024. This was driven primarily by a $12.4 million (135.3%) increase in R&D expenses due to the ramp-up of the Phase 2a trial for DA-1241 and the Phase 1 trial for DA-1726.
- Net Loss: Net loss more than doubled to $27.6 million from $12.5 million in 2023.
- Financing Activity: In June 2024, the company raised approximately $20.0 million in gross proceeds through a registered direct offering and a private placement (including $10.0 million from related party Dong-A ST Co., Ltd.). This contrasts with negligible financing activity in 2023.
- Other Income: Total other income decreased by $2.2 million to $1.2 million, primarily due to a lower gain on the change in fair value of warrant liabilities ($0.3 million in 2024 vs. $3.0 million in 2023).
Guidance, Outlook, Risks, and Contingencies
Outlook and Clinical Milestones
- DA-1241 (MASH): The Phase 2a trial completed its last patient visit in November 2024. Positive top-line 16-week results were announced in December 2024, showing statistically significant reductions in ALT levels. The Clinical Study Report (CSR) is expected in the first half of 2025.
- DA-1726 (Obesity): Positive top-line data from the Single Ascending Dose (SAD) Part 1 of the Phase 1 trial was announced in September 2024. Top-line results from the Multiple Ascending Dose (MAD) Part 2 study are expected in April 2025.
- Liquidity: Management believes existing cash ($16.0 million) is sufficient to fund operations into the third quarter of 2025. The company anticipates continuing to incur net losses and negative cash flows for the foreseeable future.
Risks and Contingencies
- Going Concern: The company has identified substantial doubt about its ability to continue as a going concern within one year of the report issuance due to recurring losses and negative cash flows. Continued operations depend on securing additional capital.
- Internal Controls: The company identified material weaknesses in internal control over financial reporting, specifically regarding logical access to accounting software and lack of review over reconciliation of accrued clinical trial liabilities. Remediation efforts are underway.
- Related Party Dependence: Dong-A ST Co., Ltd. owns approximately 62% of the company's voting stock and is the sole manufacturer for DA-1241 and DA-1726. The company is obligated to pay Dong-A regulatory milestones (up to $178 million for DA-1726 and $138 million for DA-1241) and single-digit royalties upon commercialization.
- Regulatory Risk: Success depends on obtaining FDA approval, which is uncertain. Clinical trial results may not be predictive of later-stage outcomes.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $16.0 million cash balance to fund operations through Q3 2025 and the status of any new financing efforts.
- Clinical Data Finalization: Monitor the release of the full Clinical Study Report (CSR) for the DA-1241 Phase 2a trial and the MAD Part 2 data for DA-1726 in 2025 to confirm the positive top-line results.
- Internal Control Remediation: Track the progress of remediation for the identified material weaknesses in financial reporting controls.
- Related Party Obligations: Assess the potential cash impact of future milestone payments to Dong-A ST Co., Ltd. if regulatory or commercial milestones are achieved.
- Stock Ownership: Note that Dong-A ST Co., Ltd. controls approximately 62% of voting rights, which may influence corporate decisions.